Crispr Therapeutics AG (1CG) Stock Statistics & Valuation Metrics

Crispr Therapeutics AG has a market cap or net worth of EUR 3.92B. The enterprise value is EUR 3.86B.

Market Cap

EUR 3.92B

Enterprise Value

EUR 3.86B

Crispr Therapeutics AG has 97,000,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

97,000,820

Owned by Insiders

2.60%

Owned by Institutions

39.92%

Crispr Therapeutics AG’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -26.62%.

Return on Equity (ROE)

-0.30

Return on Assets (ROA)

-0.26

Return on Invested Capital (ROIC)

-26.62%

Return on Capital Employed (ROCE)

-0.27

Revenue Per Employee

8,931.298

Profits Per Employee

-1.48M

Employee Count

393

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Crispr Therapeutics AG is -9.53. Crispr Therapeutics AG’s PEG ratio is -1.17.

PE Ratio

-9.53

PS Ratio

173.99

PB Ratio

2.65

Price to FCF

-11.55

Price to Operating Cash Flow

-11.66

PEG Ratio

-1.17

In the last 12 months, Crispr Therapeutics AG had revenue of 3.51M and earned -581.60M in profits. Earnings per share was -6.47.

Revenue

3.51M

Gross Profit

-229.45M

Operating Income

-568.32M

Pretax Income

-577.97M

Net Income

-581.60M

EBITDA

-558.49M

Earnings Per Share (EPS)

-6.47

In the last 12 months, operating cash flow was -374.63M and capital expenditures -4.56M, giving a free cash flow of -379.19M billion.

Operating Cash Flow

-374.63M

Free Cash Flow

-379.19M

Free Cash Flow per Share

-3.92

Crispr Therapeutics AG pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-8.36%

Earnings Yield

-10.08%

Beta

0.82

52-Week Price Change

-22.59%

50-Day Moving Average

46.84

200-Day Moving Average

45.59

Relative Strength Index (RSI)

45.09

Average Volume (3m)

194

Crispr Therapeutics AG upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 02, 2026

Next Earnings Date

Feb 16, 2027

Ex-Dividend Date

―

Crispr Therapeutics AG as a current ratio of 13.32, with Debt / Equity ratio of 20.55%

Current Ratio

13.32

Quick Ratio

13.32

Debt to Market Cap

0.04

Net Debt to EBITDA

-0.07

Interest Coverage Ratio

0.00

In the past 12 months, Crispr Therapeutics AG has paid 3.63M in taxes.

Income Tax

3.63M

Effective Tax Rate

-0.01

Crispr Therapeutics AG EV to EBITDA ratio is -11.15, with an EV/FCF ratio of -13.51.

EV to Sales

203.58

EV to EBITDA

-11.15

EV to Free Cash Flow

-13.51

EV to Operating Cash Flow

-13.68

Crispr Therapeutics AG has EUR 2.27B in cash and marketable securities with EUR 779.83M in debt, giving a net cash position of EUR 1.49B billion.

Cash & Marketable Securities

EUR 2.27B

Total Debt

EUR 779.83M

Net Cash

EUR 1.49B

Net Cash Per Share

EUR 15.39

Tangible Book Value Per Share

EUR 17.04

Gross margin is -676.53%, with operating margin of -2104.93%, and net profit margin of -1812.07%.

Gross Margin

-676.53%

Operating Margin

-2104.93%

Pretax Margin

-1802.19%

Net Profit Margin

-1812.07%

EBITDA Margin

-1826.44%

EBIT Margin

-1899.93%

The average price target for Crispr Therapeutics AG is EUR 64.32, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 64.32

Price Target Upside

56.77% Upside

Analyst Consensus

Moderate Buy

Analyst Count

13

Revenue Growth Forecast

-39.28%

EPS Growth Forecast

18.68%

Smart Score

3

AI Score

―